Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Intellia Therapeutics (NTLA) Invested Capital (2016 - 2026)

Intellia Therapeutics has reported Invested Capital over the past 12 years, most recently at $620.9 million for Q1 2026.

  • Quarterly Invested Capital fell 20.38% to $620.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $620.9 million through Mar 2026, down 20.38% year-over-year, with the annual reading at $671.4 million for FY2025, 23.0% down from the prior year.
  • Invested Capital was $620.9 million for Q1 2026 at Intellia Therapeutics, down from $671.4 million in the prior quarter.
  • Over five years, Invested Capital peaked at $1.2 billion in Q4 2022 and troughed at $620.9 million in Q1 2026.
  • The 5-year median for Invested Capital is $953.8 million (2022), against an average of $920.9 million.
  • Year-over-year, Invested Capital surged 77.96% in 2022 and then dropped 26.34% in 2025.
  • A 5-year view of Invested Capital shows it stood at $1.2 billion in 2022, then decreased by 15.01% to $1.1 billion in 2023, then fell by 16.97% to $872.0 million in 2024, then dropped by 23.0% to $671.4 million in 2025, then dropped by 7.51% to $620.9 million in 2026.
  • Per Business Quant, the three most recent readings for NTLA's Invested Capital are $620.9 million (Q1 2026), $671.4 million (Q4 2025), and $748.4 million (Q3 2025).